NASDAQ:STAA - STAAR Surgical Stock Price, News, & Analysis

STAAR Surgical trades on the NASDAQ under the ticker symbol "STAA."

STAAR Surgical (NASDAQ:STAA) posted its quarterly earnings data on Wednesday, August, 1st. The medical instruments supplier reported $0.09 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $0.01 by $0.08. The medical instruments supplier earned $33.91 million during the quarter, compared to analyst estimates of $27.10 million. STAAR Surgical had a net margin of 3.15% and a return on equity of 16.04%. View STAAR Surgical's Earnings History.

STAAR Surgical is scheduled to release their next quarterly earnings announcement on Wednesday, November, 14th 2018. View Earnings Estimates for STAAR Surgical.

4 Wall Street analysts have issued twelve-month price targets for STAAR Surgical's stock. Their forecasts range from $21.00 to $45.00. On average, they expect STAAR Surgical's stock price to reach $36.3333 in the next year. This suggests that the stock has a possible downside of 15.9%. View Analyst Price Targets for STAAR Surgical.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for STAAR Surgical in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for STAAR Surgical.

STAAR Surgical saw a increase in short interest during the month of July. As of July 13th, there was short interest totalling 922,701 shares, an increase of 24.9% from the June 29th total of 738,591 shares. Based on an average trading volume of 177,075 shares, the days-to-cover ratio is currently 5.2 days. Approximately 2.2% of the shares of the stock are short sold. View STAAR Surgical's Current Options Chain.

Some companies that are related to STAAR Surgical include SAGE Therapeutics (SAGE), NMC Health (NMC), Ionis Pharmaceuticals (IONS), Alkermes (ALKS), BIO-TECHNE (TECH), GN STORE NORD A/ADR (GNNDY), PRA Health Sciences (PRAH), Amneal Pharmaceuticals (AMRX), Canopy Growth (WEED), Hill-Rom (HRC), athenahealth (ATHN), ICU Medical (ICUI), LivaNova (LIVN), EXACT Sciences (EXAS) and STADA Arzneimittel (STDAF).

Headlines about STAA stock have trended somewhat positive this week, according to Accern Sentiment Analysis. Accern identifies negative and positive press coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. STAAR Surgical earned a media and rumor sentiment score of 0.16 on Accern's scale. They also gave news coverage about the medical instruments supplier an impact score of 45.51 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company's share price in the immediate future. View Recent Headlines for STAAR Surgical.

STAAR Surgical's stock is owned by many different of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (6.79%), Putnam Investments LLC (5.96%), Baillie Gifford & Co. (2.78%), Renaissance Technologies LLC (1.48%), Millennium Management LLC (1.40%) and Fuller & Thaler Asset Management Inc. (0.86%). Company insiders that own STAAR Surgical stock include Caren L Mason, Deborah J Andrews, Hans-Martin Blickensdoerfer, Keith Holliday, Samuel J Gesten and William P Wall. View Institutional Ownership Trends for STAAR Surgical.

STAA stock was sold by a variety of institutional investors in the last quarter, including Putnam Investments LLC, Cortina Asset Management LLC, Rice Hall James & Associates LLC, Quantum Capital Management, Grandeur Peak Global Advisors LLC, King Luther Capital Management Corp, Bank of America Corp DE and Voya Investment Management LLC. Company insiders that have sold STAAR Surgical company stock in the last year include Caren L Mason, Deborah J Andrews, Keith Holliday, Samuel J Gesten and William P Wall. View Insider Buying and Selling for STAAR Surgical.

STAA stock was acquired by a variety of institutional investors in the last quarter, including Fuller & Thaler Asset Management Inc., Millennium Management LLC, Renaissance Technologies LLC, Acadian Asset Management LLC, BNP Paribas Arbitrage SA, ClariVest Asset Management LLC, EAM Investors LLC and BlackRock Inc.. View Insider Buying and Selling for STAAR Surgical.

Shares of STAA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of STAA stock can currently be purchased for approximately $43.20.

STAAR Surgical has a market capitalization of $1.80 billion and generates $90.61 million in revenue each year. The medical instruments supplier earns $-2,130,000.00 in net income (profit) each year or $0.01 on an earnings per share basis. STAAR Surgical employs 353 workers across the globe.

STAAR Surgical's mailing address is 1911 WALKER AVENUE, MONROVIA CA, 91016. The medical instruments supplier can be reached via phone at 626-303-7902 or via email at [email protected]